|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Boyle P and Levin B: World Cancer Report
2008. IARC Scientific Publications; Lyon: 2008
|
|
3
|
Curado MP, Edwards B, Shin HR, Storm H,
Ferlay J, Heanue M and Boyle P: Cancer Incidence in Five
Continents. IX. IARC Scientific Publications; Lyon: 2007
|
|
4
|
Terasaki H, Niki T, Matsuno Y, et al: Lung
adenocarcinoma with mixed bronchioloalveolar and invasive
components: clinicopathological features, subclassification by
extent of invasive foci, and immunohistochemical characterization.
Am J Surg Pathol. 27:937–951. 2003. View Article : Google Scholar
|
|
5
|
Travis WD, Brambilla E, Noguchi M, et al:
International Association for the Study of Lung Cancer/American
Thoracic Society/European Respiratory Society international
multidisciplinary classification of lung adenocarcinoma. J Thorac
Oncol. 6:244–285. 2011. View Article : Google Scholar
|
|
6
|
Travis WD, Brambilla E, Muller-Hermelink
HK and Harris CC: Pathology and Genetics of Tumours of the Lung,
Pleura, Thymus and Heart. IARC Press; Lyon: 2004
|
|
7
|
Travis WD, Colby TV, Corrin B, Shimosato Y
and Brambilla E: Histological Typing of Lung and Pleural Tumors.
3rd edition. Springer; Berlin: 1999, View Article : Google Scholar
|
|
8
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. New Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Riely GJ, Politi KA, Miller VA and Pao W:
Update on epidermal growth factor receptor mutations in non-small
cell lung cancer. Clin Cancer Res. 12:7232–7241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sakai K, Arao T, Shimoyama T, et al:
Dimerization and the signal transduction pathway of a small
in-frame deletion in the epidermal growth factor receptor. FASEB J.
20:311–313. 2006.PubMed/NCBI
|
|
11
|
Soda M, Choi YL, Enomoto M, et al:
Identification of the transforming EML4-ALK fusion gene in
non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kwak EL, Bang YJ, Camidge DR, et al:
Anaplastic lymphoma kinase inhibition in non-small-cell lung
cancer. New Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gandhi L and Janne PA: Crizotinib for
ALK-rearranged non-small cell lung cancer: a new targeted therapy
for a new target. Clin Cancer Res. 18:3737–3742. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rodig SJ, Mino-Kenudson M, Dacic S, et al:
Unique clinicopathologic features characterize ALK-rearranged lung
adenocarcinoma in the western population. Clin Cancer Res.
15:5216–5223. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mino-Kenudson M, Chirieac LR, Law K, et
al: A novel, highly sensitive antibody allows for the routine
detection of ALK-rearranged lung adenocarcinomas by standard
immunohistochemistry. Clin Cancer Res. 16:1561–1571. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
ten Hoeve J, Kaartinen V, Fioretos T, et
al: Cellular interactions of CRKL and SH2-SH3 adaptor protein.
Cancer Res. 54:2563–2567. 1994.PubMed/NCBI
|
|
17
|
Senechal K, Halpern J and Sawyers CL: The
CRKL adaptor protein transforms fibroblasts and functions in
transformation by the BCR-ABL oncogene. J Biol Chem.
271:23255–23261. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hafizi S and Dahlback B: Signalling and
functional diversity within the Axl subfamily of receptor tyrosine
kinases. Cytokine Growth Factor Rev. 17:295–304. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goruppi S, Ruaro E, Varnum B and Schneider
C: Requirement of phosphatidylinositol 3-kinase-dependent pathway
and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3
fibroblasts. Mol Cell Biol. 17:4442–4453. 1997.PubMed/NCBI
|
|
20
|
Hector A, Montgomery EA, Karikari C, et
al: The Axl receptor tyrosine kinase is an adverse prognostic
factor and a therapeutic target in esophageal adenocarcinoma.
Cancer Biol Ther. 10:1009–1018. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Z, Lee JC, Lin L, et al: Activation
of the AXL kinase causes resistance to EGFR-targeted therapy in
lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Paccez JD, Vasques GJ, Correa RG, et al:
The receptor tyrosine kinase Axl is an essential regulator of
prostate cancer proliferation and tumor growth and represents a new
therapeutic target. Oncogene. 32:689–698. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cai YR, Zhang HQ, Qu Y, et al: Expression
of MET and SOX2 genes in non-small cell lung carcinoma with EGFR
mutation. Oncol Rep. 26:877–885. 2011.PubMed/NCBI
|
|
24
|
Lee HJ, Xu X, Choe G, et al: Protein
overexpression and gene amplification of epidermal growth factor
receptor in nonsmall cell lung carcinomas: Comparison of four
commercially available antibodies by immunohistochemistry and
fluorescence in situ hybridization study. Lung Cancer. 68:375–382.
2010. View Article : Google Scholar
|
|
25
|
Motoi N, Szoke J, Riely GJ, et al: Lung
adenocarcinoma: modification of the 2004 WHO mixed subtype to
include the major histologic subtype suggests correlations between
papillary and micropapillary adenocarcinoma subtypes, EGFR
mutations and gene expression analysis. Am J Surg Pathol.
32:810–827. 2008. View Article : Google Scholar
|
|
26
|
Sica G, Yoshizawa A, Sima CS, et al: A
grading system of lung adenocarcinomas based on histologic pattern
is predictive of disease recurrence in stage I tumors. Am J Surg
Pathol. 34:1155–1162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
De Oliveira Duarte Achcar R, Nikiforova MN
and Yousem SA: Micropapillary lung adenocarcinoma: EGFR, K-ras and
BRAF mutational profile. Am J Clin Pathol. 131:694–700.
2009.PubMed/NCBI
|
|
28
|
Kim YH, Ishii G, Goto K, et al: Dominant
papillary subtype is a significant predictor of the response to
gefitinib in adenocarcinoma of the lung. Clin Cancer Res.
10:7311–7317. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ding L, Getz G, Wheeler DA, et al: Somatic
mutations affect key pathways in lung adenocarcinoma. Nature.
455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Okudela K, Woo T, Mitsui H, et al:
Proposal of an improved histological sub-typing system for lung
adenocarcinoma - significant prognostic values for stage I disease.
Int J Clin Exp Pathol. 3:348–366. 2010.
|
|
31
|
Amin MB, Tamboli P, Merchant SH, et al:
Micropapillary component in lung adenocarcinoma: a distinctive
histologic feature with possible prognostic significance. Am J Surg
Pathol. 26:358–364. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tsutsumida H, Nomoto M, Goto M, et al: A
micropapillary pattern is predictive of a poor prognosis in lung
adenocarcinoma and reduced surfactant apoprotein A expression in
the micropapillary pattern is an excellent indicator of a poor
prognosis. Mod Pathol. 20:638–647. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yoshizawa A, Motoi N, Riely GJ, et al:
Impact of proposed IASLC/ATS/ERS classification of lung
adenocarcinoma: prognostic subgroups and implications for further
revision of staging based on analysis of 514 stage I cases. Mod
Pathol. 24:653–664. 2011. View Article : Google Scholar
|
|
34
|
Cheung HW, Du J, Boehm JS, et al:
Amplification of CRKL induces transformation and epidermal growth
factor receptor inhibitor resistance in human non-small cell lung
cancers. Cancer Discov. 1:608–625. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Finberg KE, Sequist LV, Joshi VA, et al:
Mucinous differentiation correlates with absence of EGFR mutation
and presence of KRAS mutation in lung adenocarcinomas with
bronchioloalveolar features. J Mol Diagn. 9:320–326. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Suda K, Murakami I, Katayama T, et al:
Reciprocal and complementary role of MET amplification and EGFR
T790M mutation in acquired resistance to kinase inhibitors in lung
cancer. Clin Cancer Res. 16:5489–5498. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang X, Gureasko J, Shen K, Cole PA and
Kuriyan J: An allosteric mechanism for activation of the kinase
domain of epidermal growth factor receptor. Cell. 125:1137–1149.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Takeuchi K, Choi YL, Togashi Y, et al:
KIF5B-ALK, a novel fusion oncokinase identified by an
immunohistochemistry-based diagnostic system for ALK-positive lung
cancer. Clin Cancer Res. 15:3143–3149. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Boland JM, Erdogan S, Vasmatzis G, et al:
Anaplastic lymphoma kinase immunoreactivity correlates with ALK
gene rearrangement and transcriptional up-regulation in non-small
cell lung carcinomas. Hum Pathol. 40:1152–1158. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shaw AT, Yeap BY, Mino-Kenudson M, et al:
Clinical features and outcome of patients with non-small-cell lung
cancer who harbor EML4-ALK. J Clin Oncol. 27:4247–4253. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Takahashi T, Sonobe M, Kobayashi M, et al:
Clinicopathologic features of non-small-cell lung cancer with
EML4-ALK fusion gene. Ann Surg Oncol. 17:889–897. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
O’Bryan JP, Frye RA, Cogswell PC, et al:
Axl, a transforming gene isolated from primary human myeloid
leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell
Biol. 11:5016–5031. 1991.PubMed/NCBI
|
|
43
|
Neubauer A, O’Bryan JP, Fiebeler A,
Schmidt C, Huhn D and Liu ET: Axl, a novel receptor tyrosine kinase
isolated from chronic myelogenous leukemia. Semin Hematol. 30(3
Suppl 3)34:1993
|
|
44
|
Lee HY, Han J, Lee KS, et al: Lung
adenocarcinoma as a solitary pulmonary nodule: prognostic
determinants of CT, PET, and histopathologic findings. Lung Cancer.
66:379–385. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yokose T, Suzuki K, Nagai K, Nishiwaki Y,
Sasaki S and Ochiai A: Favorable and unfavorable morphological
prognostic factors in peripheral adenocarcinoma of the lung 3 cm or
less in diameter. Lung Cancer. 29:179–188. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lin DM, Ma Y, Zheng S, Liu XY, Zou SM and
Wei WQ: Prognostic value of bronchioloalveolar carcinoma component
in lung adenocarcinoma. Histol Histopathol. 21:627–632.
2006.PubMed/NCBI
|
